AbbVie Inc (ABBV)vsRhythm Pharmaceuticals Inc (RYTM)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
RYTM
Rhythm Pharmaceuticals Inc
$86.40
-1.38%
HEALTHCARE · Cap: $6.06B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 28827% more annual revenue ($62.82B vs $217.16M). ABBV leads profitability with a 5.8% profit margin vs -93.3%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RYTM
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for RYTM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 83.8% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Elevated debt levels
Trading at 48.0x book value
ROE of -164.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : RYTM
The strongest argument for RYTM centers on Revenue Growth. Revenue growth of 83.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : RYTM
The primary concerns for RYTM are EPS Growth, Debt/Equity, Price/Book. Debt-to-equity of 1.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while RYTM is a hypergrowth play — different risk/reward profiles.
RYTM carries more volatility with a beta of 1.92 — expect wider price swings.
RYTM is growing revenue faster at 83.8% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Rhythm Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?